不可切除IIIB-IIID期伴卫星或移行转移黑色素瘤的临床特征与治疗反应
该多中心回顾性研究纳入191例初诊不可切除III期伴移行/卫星转移的皮肤黑色素瘤患者,分析肿瘤特征、生存及治疗反应。中位随访30.5个月,56.5%进展至IV期;无远处进展者多为女性、>70岁且原发灶位于腿部。局部一线治疗ORR 38%、DCR 49%;靶向治疗ORR 63.2%高于PD-1的31.4%。
要点
- 无远处进展的不可切除III期ITM患者多为女性、高龄且原发灶在腿部。
- 局部一线治疗ORR 38%、DCR 49%;靶向治疗ORR 63.2%高于PD-1的31.4%。
- PD-1联合病灶内T-VEC的ORR 41.7%、DCR 75%。
核心结论
- 不可切除ITM无远处进展者多为女性、年龄>70岁且原发灶位于腿部。
- 该队列PD-1抑制剂疗效低于预期,需进一步研究ITM生物学及免疫系统交互作用。
研究设计与样本
- 多中心回顾性研究,纳入16个皮肤癌中心191例初诊不可切除III期ITM和卫星转移患者。
- 按疾病动力学分为无远处进展、慢速(>6个月)和快速(<6个月)远处进展三组分别分析。
主要发现
- 中位随访30.5个月(范围0.8-154.0),56.5%进展至IV期。
- 无远处转移者中45.7%初诊即为III期伴淋巴结或ITM。
- 原发灶位于腿部者自初诊起OS显著优于非腿部(HR=0.61,95%CI 0.40-0.91;p=0.017),自不可切除III期诊断起差异不显著(HR=0.67,95%CI 0.45-1.02;p=0.06)。
关键数值与推荐
- 40%患者接受卫星和ITM局部治疗,局部一线治疗ORR 38%、DCR 49%。
- 72.3%患者接受不可切除IIIB-D期系统治疗。
- 靶向治疗(n=19)ORR 63.2%、DCR 84.2%;PD-1治疗(n=70)ORR 31.4%、DCR 54.3%。
- PD-1联合病灶内T-VEC(n=12)ORR 41.7%、DCR 75%。
临床怎么用
- 对不可切除III期ITM患者应评估疾病动力学以指导治疗分层。
- 靶向治疗在该队列中显示较高ORR,PD-1抑制剂疗效需结合预期谨慎评估。
局限性
- 回顾性研究设计,样本来自16个皮肤癌中心,可能存在选择偏倚。
- 部分亚组样本量较小(如靶向治疗n=19、联合治疗n=12)。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: Cutaneous melanoma is notorious for the development of in-transit metastases (ITM). For unknown biological reasons, ITM remain the leading tumour manifestation without progression to distant sites in some patients. METHODS: In total, 191 patients with initially unresectable stage III ITM and satellite metastases from 16 skin cancer centres were retrospectively evaluated for their tumour characteristics, survival and therapy response. Three groups according to disease kinetics (no distant progress, slow (>6 months) and fast (<6 months) distant progression) were analysed separately. RESULTS: Median follow-up time was 30.5 (range 0.8-154.0) months from unresectable ITM. Progression to stage IV was observed in 56.5% of cases. Patients without distant metastasis were more often female, older (>70 years) and presented as stage III with lymph node or ITM at initial diagnosis in 45.7% of cases. Melanoma located on the leg had a significantly better overall survival (OS) from time of initial diagnosis compared to non-leg localised primaries (hazard ratio [HR] = 0.61, 95% confidence interval [CI] 0.40-0.91; p = 0.017), but not from diagnosis of unresectable stage III (HR = 0.67, 95% CI 0.45-1.02; p = 0.06). Forty percent of patients received local therapy for satellite and ITM. Overall response rate (ORR) to all local first-line treatments was 38%; disease control rate (DCR) was 49%. In total, 72.3% of patients received systemic therapy for unresectable stage IIIB-D. ORR for targeted therapy (n = 19) was highest with 63.2% and DCR was 84.2% compared to an ORR of 31.4% and a DCR of 54.3% in PD-1 treated patients (n = 70). Patients receiving PD-1 and intralesional talimogene laherparepvec (n = 12) had an ORR of 41.7% and a DCR of 75%. CONCLUSION: Patients with unresectable ITM and without distant progression are more often female, older, and have a primary on the leg. Response to PD-1 inhibitors in this cohort was lower than expected, but further investigation is required to elucidate the biology of ITM development and the interplay with the immune system.
引用
- Zaremba A, Philip M, Hassel JC, et al. Clinical characteristics and therapy response in unresectable melanoma patients stage IIIB-IIID with in-transit and satellite metastases. Eur J Cancer. 2021. PMID: 34102453. doi:10.1016/j.ejca.2021.04.032
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。